Atomwise vs Kepler Vision

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Atomwise employs 75 people, while Kepler Vision has 1-50 employees.

Atomwise has raised $219M in disclosed funding across 5 known rounds. Kepler Vision's funding history is not publicly available.

Atomwise holds the higher Awaira Score at 53/100, compared to Kepler Vision's 30/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 23-point gap that reflects meaningful differences in scale or traction.

Atomwise was founded by Abraham Heifets in 2012. Kepler Vision was founded by Harro Stokman in 2017. Visit each company's profile on Awaira for a full founder biography.

Atomwise: Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform leverages machine learning algorithms to screen vast chemical libraries and predict molecular interactions, enabling faster identification of promising compounds for various therapeutic areas including oncology, infectious diseases, and genetic disorders. The company has secured $219 million in total funding and operates at the Series B stage, though its current valuation remains undisclosed. Atomwise's approach combines physics-based molecular modeling with machine learning to simulate how potential drugs interact with disease targets. The platform has been applied to multiple drug discovery projects across both internal programs and partnerships with pharmaceutical companies and research institutions. Atomwise competes in the growing computational drug discovery sector alongside companies utilizing AI for pharmaceutical development. The company's technology addresses significant pain points in drug development, including extended timelines and high failure rates. Its trajectory reflects the increasing adoption of AI-driven approaches in healthcare and pharmaceutical industries, positioning it within a broader trend toward computational acceleration of biomedical research and development processes. Atomwise applies physics-informed machine learning to molecular simulation for drug discovery, combining computational chemistry with AI to accelerate preclinical pharmaceutical development. Kepler Vision: Kepler Vision Technologies develops AI fall detection and activity recognition software for elderly care environments, using computer vision models that process video from ceiling-mounted cameras in care facilities to detect falls, assess resident activity patterns, and alert care staff to incidents requiring immediate response. The Amsterdam company platform is designed to operate without wearables or pressure sensors, relying entirely on camera-based analysis to provide unobtrusive monitoring.\n\nThe company is early stage with initial funding from Dutch innovation programmes and care sector partners. Kepler Vision has piloted its Night Nurse product in Dutch residential care facilities, where staff shortages create demand for AI monitoring tools that can maintain safety oversight overnight when staffing ratios are lowest. The platform is designed to comply with European privacy regulations governing personal data processing in care environments, using on-device processing to avoid transmitting identifiable video to cloud services.\n\nKepler Vision operates in the AI elder care market alongside CarePredict, SafelyYou, and camera-based monitoring startups targeting the intersection of computer vision and residential care. The European elder care AI market faces distinct regulatory challenges compared to the US, with GDPR-compliant video monitoring in care facilities requiring explicit consent frameworks and data minimisation approaches. The Netherlands position as a leader in healthcare technology innovation and its advanced residential care infrastructure make it a relevant test market for technology that addresses the growing caregiver shortage across European social care systems.

Atomwise was founded first in 2012, giving it 5 years of additional market experience. Kepler Vision was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Atomwise has approximately 75 employees, while Kepler Vision has approximately 1-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Atomwise and Kepler Vision are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.